A quantitative survey of the literature on poliovirus infection and immunity

International Journal of Infectious Diseases

Volumn 18, Issue 1, 2014, Pages 4-13

  Behrend, Matthew R ^a   Hu, Hao ^a   Nigmatulina, Karima R ^a   Eckhoff, Philip ^a  

^a Intellectual Ventures   (United States)

Author keywords

Immunogenicity; Inactivated polio vaccine, IPV; Model; Oral polio vaccine, OPV; Polio eradication; Poliovirus vaccine efficacy

Indexed keywords

ORAL POLIOMYELITIS VACCINE; POLIOMYELITIS VACCINE;

DISEASE ERADICATION; HEALTH CARE POLICY; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INFORMATION RETRIEVAL; MASS IMMUNIZATION; POLIOMYELITIS; QUANTITATIVE ANALYSIS; REVIEW; VACCINE FAILURE;

IMMUNOGENICITY; INACTIVATED POLIO VACCINE, IPV; MODEL; ORAL POLIO VACCINE, OPV; POLIO ERADICATION; POLIOVIRUS VACCINE EFFICACY;

HUMANS; IMMUNITY; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; MODELS, IMMUNOLOGICAL; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; VACCINATION;

EID: 84891560773     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2013.09.005     Document Type: Review

References (106)

1. Chumakov K., Ehrenfeld E., Wimmer E., Agol V.I. Vaccination against polio should not be stopped. Nat Rev Microbiol 2007, 5:952-958.
2. Donaldson S.L., Toole M., El Sayed N., de Quadros C., Koplan J., Mogedal S., et al. Report of the Independent Monitoring Board of the Global Polio Eradication Initiative: February 2012 2012, IMB, London.
3. Wassilak S., Orenstein W. Challenges faced by the global polio eradication initiative. Expert Rev Vaccines 2010, 9:447-449.
4. Wassilak S., Pate M.A., Wannemuehler K., Jenks J., Burns C., Chenoweth P., et al. Outbreak of type 2 vaccine-derived poliovirus in Nigeria: Emergence and widespread circulation in an underimmunized population. J Infect Dis 2011, 203:898-909.
5. Kew O.M., Sutter R.W., de Gourville E.M., Dowdle W.R., Pallansch M.A. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Ann Rev Microbiol 2005, 59:587-635.
6. Minor P. Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication. Vaccine 2009, 27:2649-2652.
7. Vidor E., Plotkin S.A. Poliovirus vaccine-inactivated. Vaccines 2013, Elsevier Health Sciences, ch 27:573-597. 6th Edition. S.A. Plotkin, W.A. Orenstein, Offit PA (Eds.).
8. Sutter R.W., Kew O.M., Cochi S.L. Aylward RB. Poliovirus vaccine-live. Vaccines 2013, Elsevier Health Sciences, ch 28:598-647. 6th Edition,. S.A. Plotkin, W.A. Orenstein, Offit PA (Eds.).
9. Grassly Nicholas C., Jafari H., Bahl S., Durrani S., Wenger J., Sutter Roland W., Aylward R.B. Mucosal immunity after vaccination with monovalent and trivalent oral poliovirus vaccine in India. J Infect Dis 2009, 200:794-801.
10. Jenkins H.E., Aylward R.B., Gasasira A., Donnelly C.A., Mwanza M., Corander J., et al. Implications of a circulating vaccine-derived poliovirus in Nigeria. N Engl J Med 2010, 362:2360-2369.
11. Hird T.R., Grassly N.C. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012, 8:e1002599.
12. Duintjer Tebbens R.J., Pallansch M.A., Chumakov K.M., Halsey N.A., Hovi T., Minor P.D., et al. Expert review on poliovirus immunity and transmission. Risk Anal 2013, 33:544-605.
13. Plotkin S.A., Orenstein W.A., Offit P.A. Vaccines 2008, Elsevier Health Sciences. 5th Edition.
14. Alexander J.P., Gary H.E., Pallansch M.A. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J Infect Dis 1997, 175(S1):S176-S182.
15. Fine P.E., Carneiro I.A. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol 1999, 150:1001-1021.
16. Robertson S. Expanded Program on Immunization. The immunological basis for immunization series: module 6-poliomyelitis 1993, World Health Organization, Geneva.
17. Balsamo A., Mana G., Pennecchi F. The expression of uncertainty in non-linear parameter estimation. Metrologia 2006, 43:396-402.
18. Abbink F., Buisman A.M., Doornbos G., Woldman J., Kimman Tjeerd G., Conyn-van Spaendonck M.A. Poliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis 2005, 191:990-999.
19. Abraham R., Minor P., Dunn G., Modlin J.F., Ogra P.L. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J Infect Dis 1993, 168:1105-1109.
20. Dong D-x, Hu X-m., Liu W-j, Li J-s, Jin Y-c, Tan S-g, et al. Immunization of neonates with trivalent oral poliomyelitis vaccine (Sabin). Bull World Health Organ 1986, 64:853-860.
21. El-Sayed N., El-Gamal Y., Abbassy A.-A., Seoud I., Salama M., Kandeel A., et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Engl J Med 2008, 359:1655-1665.
22. Ghendon Y.Z., Sanakoyeva I.I. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin's strains) in persons after naturally and experimentally acquired immunity. Acta Virol 1961, 5:265-273.
23. Glezen W.P., McCollough R.H., Lamb G.A., Chin T.D.Y. Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus type 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. Am J Epidemiol 1969, 90:146-156.
24. Goffe A., Pollock T.M., Shand F.L. Vaccination of adults with a British oral poliomyelitis vaccine prepared from Sabin strains. Br Med J 1961, 2:272-274.
25. Henry J.L., Jaikaran E.S., Davies J.R., Tomlinson A.J.H., Mason P.J., Barnes J.M., Beale A.J. A study of poliovaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine. J Hyg (Lond.) 1966, 64:105-120.
26. Laassri M., Lottenbach K., Belshe R., Wolff M., Rennels M., Plotkin S., Chumakov K. Effect of different vaccination schedules on excretion of oral poliovirus vaccine strains. J Infect Dis 2005, 192:2092-2098.
27. Lu C., Kao C., Lee C., Lee P., Huang L. Immunogenicity and fecal poliovirus excretion in sequential use of inactivated and oral poliovirus vaccines. J Formos Med Assoc 2001, 100:513-518.
28. Maldonado Y.A., Peña-Cruz V., de la Luz Sanchez M., Logan L., Blandón S., Cantwell M.F., et al. Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J Infect Dis 1997, 175:545-553.
29. Mallet L., Pelloquin F., Brigaud M., Caudrelier P., Bandet R., Xueref C., et al. Comparative study of poliovirus excretion after vaccination of infants with two oral polio vaccines prepared on Vero cells or on primary monkey kidney cells. J Med Virol 1997, 52:50-60.
30. Modlin J.F., Halsey N.A., Thoms M.L., Meschievitz C.K., Patriarca P.A. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. J Infect Dis 1997, 175(S1):S228-S234.
31. Nishio O., Ishihara Y., Sakae K., Nonomura Y., Kuno A., Yasukawa S., et al. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. J Biol Stand 1984, 12:1-10.
32. Ogra P.L., Faden H.S., Abraham R., Duffy L.C., Sun M., Minor P.D. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines. J Infect Dis 1991, 6(S2):191-194.
33. Onorato I.M., Modlin J.F., McBean A.M., Thoms M.L., Losonsky G.A., Bernier R.H. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991, 163:1-6.
34. PHLS. The excretion of type 1 poliovirus after challenge following primary immunization with quadruple, Salk and Sabin vaccines. Mon Bull Minist Health Public Health Lab Serv. Nov 1965;24:365-9.
35. Smith J.W.G., Lee J.A., Fletcher W.B., Morris C.A., Parker D.A., Yetts R., et al. The response to oral poliovaccine in persons aged 16-18 years. J Hyg (Lond.) 1976, 76:235-247.
36. Swartz T., Green M., Handscher R., Sofer D., Cohendar M., Shohat T., et al. Intestinal immunity following a combined enhanced inactivated polio vaccine/oral polio vaccine programme in Israel. Vaccine 2008, 26:1083-1090.
37. Verlinde J.D., Wilterdink J.B. A small-scale trial on vaccination and revaccination with live attenuated polioviruses in the Netherlands 1959, 355-366. Pan American Health Organization, Washington, D.C., (Scientific publication no. 44.).
38. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in the Gambia, Oman, and Thailand. J Infect Dis 1997; 175(S1):S215-27.
39. Horstmann D.M., Paul J.R., Godenne-McCrea M., Green R.H., Opton E.M., Holtz A.I., Niederman J.C. Immunization of preschool children with oral poliovirus vaccine (Sabin). JAMA 1961, 178:101-109.
40. Vaccine Administration Subcommittee. Evaluation of Sabin live poliovirus vaccine in Japan II. Clinical, virologic and immunological effects of vaccine in children. Jpn J Med Sci Biol 1966;19:277-91.
41. Parent du Chatelet I., Merchant A.T., Fisher-Hoch S., Lubyb S.P., Plotkin S.A., Moatter T., et al. Serological response and poliovirus excretion following different combined oral and inactivated poliovirus vaccines immunization schedules. Vaccine 2003, 21:1710-1718.
42. Sutter R.W., Suleiman A.J.M., Malankar P., Al-Khusaiby S., Mehta F., Clements G., et al. Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 2000, 343:767-773.
43. Asturias Edwin J., Dueger Erica L., Omer Saad B., Melville A., Nates Silvia V., Laassri M., et al. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants. J Infect Dis 2007, 196:692-698.
44. Dick G.W., Dane D.S., McAlister J., Nelson R., Field C.M. Vaccination against poliomyelitis with live virus vaccines 7. Effect of previous Salk vaccination on virus excretion. Br Med J 1961, 2:266-269.
45. Galindo M. Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba. N Engl J Med 2007, 356:1536-1544. The Cuba IPV Collaborative Study Group.
46. Glezen W.P., Lamb G.A., Belden E.A., Chin T.D. Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol 1966, 83:224-237.
47. Ion-Nedelcu N., Strebel P.M., Toma F., Biberi-Moroeanu S., Combiescu M., Persu A., et al. Sequential and combined use of inactivated and oral poliovirus vaccines: Dolj District, Romania, 1992-1994. J Infect Dis 1997, 175(S1):S241-S246.
48. Kogon A., Spigland I., Elveback L., Fox J.P. Oral poliovirus vaccination in middle income families. Am J Epidemiol 1965, 82:14-26.
49. Pagano J.S., Bottiger M., Bonnevier J.O., Gard S. The response and the lack of spread in Swedish school children given an attenuated poliovirus vaccine prepared in a human diploid cell strain. Am J Hyg 1964, 79:74-85.
50. Gelfand H.M., Potash L., LeBlanc D.R., Fox J.P. Intrafamilial and interfamilial spread of living vaccine strains of polioviruses. JAMA 1959, 170:85-94.
51. Piirainen L., Stenvik M., Roivainen M., Eskola J., Beuvery E.C., Hovi T. Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus. Vaccine 1999, 17:1084-1090.
52. Gelfand H., Fox J., LeBlanc D., Elveback L. Studies on the development of natural immunity to poliomyelitis in Louisiana V. Passive transfer of polio antibody from mother to fetus and natural decline and disappearance of antibody in the infant. J Immunol 1960, 85:46-55.
53. Plotkin S.A., Koprowski H., Joseph Stokes J. Clinical trials in infants of orally administered attenuated poliomyelitis viruses. Pediatrics 1959, 23:1041-1062.
54. Resik S., Tejeda A., Lago P.M., Diaz M., Carmenates A., Sarmiento L., et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis 2010, 201:1344-1352.
55. Weckx L.Y., Schmidt B.J., Herrmann A.A., Miyasaki C.H., Novo N.F. Early immunization of neonates with trivalent oral poliovirus vaccine. Bull World Health Organ 1992, 70:85-91.
56. Smith S.J., Lawrence D.N., Noble G.R. An immune response profile model for immunogenicity quantitation. J Theor Biol 1984, 110:1-10.
57. Salk J., Cohen H., Fillastre C., Stoeckel C., Rey J.-L., Schlumberger M., et al. Killed poliovirus antigen titration in humans. Dev Biol Stand 1978, 41:119-132.
58. Teunis PFM, van der Heijden OG, van derGiessen JWB, Havelaar AH. The dose-response relation in human volunteers for gastro-intestinal pathogens. Rijksinstituut voor Volksgezondheid en Milieu (Netherlands), 1996; Report no. 284550 002.
59. Fox J.P. Modes of action of poliovirus vaccines and relation to resulting immunity. Rev Infect Dis 1984, 6(Suppl 2):S352-S355.
60. Choudhury D.S., Nossik N.N., Bindu, Vijayan P., Raghavan N.G., Paul S.S. Poliomyelitis vaccination of infants: preimmunization status and seroconversion. Bull World Health Organ 1973, 48:195-198.
61. Holguin A., Reeves J., Gelfand H. Immunization of infants with the Sabin oral poliovirus vaccine. Am J Public Health 1962, 52:600-610.
62. Swartz T.A., Skalska P., Gerichter C.G., Cockburn W.C. Routine administration of oral polio vaccine in a subtropical area. Factors possibly influencing sero-conversion rates. J Hyg (Lond.) 1972, 70:719-726.
63. Faden H., Modlin J.F., Thoms M.L., McBean A.M., Ferdon M.B., Ogra P.L. Evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 1990, 162:1291-1297.
64. Myaux J., Unicomb L., Besser R.E., Modlin J.F., Uzma A., Islam A.M., Santosham M. Effect of diarrhea on the humoral response to oral polio vaccination. Pediatr Infect Dis J 1996, 15:204-209.
65. Samoilovich E., Roivainen M., Titov L.P., Hovi T. Serotype-specific mucosal immune response and subsequent poliovirus replication in vaccinated children. J Med Virol 2003, 71:274-280.
66. Lepow M.L., Nankervis G.A., Robbins F.C. Immunity of school children two years after oral poliomyelitis vaccination. JAMA 1967, 202:121-125.
67. Swartz T.A., Handsher R., Stoeckel P., Drucker J., Caudrelier P., Wezel A.L.V., et al. Immunologic memory induced at birth by immunization with inactivated polio vaccine in a reduced schedule. Eur J Epidemiol 1989, 5:143-145.
68. Barr R.N., Bauer H., Kleinman H., Johnson E.A., da Silva M.M., Kimball A.C., Cooney M.K., et al. Use of orally administered live attenuated polioviruses as a vaccine in a community setting. J Am Med Assoc 1959, 170:67-79.
69. Moriniere B.J., van Loon F., Rhodes P.H., Klein-Zabban M.-L., Frank-Senat B., Herrington J.E., et al. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine. Lancet 1993, 341:1545-1550.
70. Estivariz C., Jafari H., Sutter R., John T., Jain V., Agarwal A., et al. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial. Lancet Infect Dis 2012, 12:128-135.
71. Carlsson R.M., Claesson B.A., Fagerlund E., Knutsson N., Lundin C. Antibody persistence in five-year-old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J 2002, 21:535-541.
72. Gelfand H.M., LeBlanc D.R., Potash L., Fox J.P. Studies on the development of natural immunity to poliomyelitis in Louisiana IV. Natural infections with polioviruses following immunization with a formalin-inactivated vaccine. Am J Hyg 1959, 70:312-327.
73. Patriarca P.A., Wright P.F., John T.J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries. Rev Infect Dis 1991, 13:926-939.
74. Serazin A.C., Shackelton L.A., Wilson C., Bhan M.K. Improving the performance of enteric vaccines in the developing world. Nat Immunol 2010, 11:769-773.
75. Humphrey J.H. Child undernutrition, tropical enteropathy, toilets, and handwashing. Lancet 2009, 374:1032-1035.
76. World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. J Infect Dis 1995;171:1097-106.
77. Idris M.Z., Mathur A., Sharma P., Chaturvedi U.C., Sharma N.L. Oral polio vaccination and factors affecting its efficacy. Indian J Med Res 1980, 71:671-678.
78. Faden H., Duffy L. Effect of concurrent viral infection on systemic and local antibody responses to live attenuated and enhanced-potency inactivated poliovirus vaccines. AJDC 1992, 146:1320-1323.
79. Deivanayagam N., Mala N., Ashok T.P., Ratnam S.R., Sankaranarayanan V.S. Risk factors for persistent diarrhea among children under 2 years of age. Case control study. Indian Pediatr 1993, 30:177-185.
80. Savy M., Edmond K., Fine P.E., Hall A., Hennig B.J., Moore S.E., et al. Landscape analysis of interactions between nutrition and vaccine responses in children. J Nutr 2009, 139. 2154S-2218S.
81. Grassly N.C., Fraser C., Wenger J., Deshpande J.M., Sutter R.W., Heymann D.L., Aylward R.B. New strategies for the elimination of polio from India. Science 2006, 314:1150-1153.
82. Grassly N.C., Wenger J., Durrani S., Bahl S., Deshpande J.M., Sutter R.W., et al. Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet 2007, 369:1356-1362.
83. Jenkins H.E., Aylward R.B., Gasasira A., Donnelly C.A., Abanida E.A., Koleosho-Adelekan T., Grassly N.C. Effectiveness of immunization against paralytic poliomyelitis in Nigeria. N Engl J Med 2008, 359:1666-1674.
84. Sutter R.W., John T.J., Jain H., Agarkhedkar S., Ramanan P.V., Verma H., et al. Immunogenicity of bivalent type 1 and 3 oral poliovirus vaccine: a randomized, double-blind clinical trial. Lancet 2010, 6736:61230-61235.
85. Simoes E.A., Padmini B., Steinhoff M.C., Jadhav M., John T.J. Antibody response of infants to two doses of inactivated poliovirus vaccine of enhanced potency. Am J Dis Child 1985, 139:977-980.
86. Dayan G.H., Thorley M., Yamamura Y., Rodriguez N., McLaughlin S., Torres L.M., et al. Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico. J Infect Dis 2007, 195:12-20.
87. Domok I., Balayan M.S., Fayinka O.A., Skrtic N., Soneji A.D., Harland P.S. Factors affecting the efficacy of live poliovirus vaccine in warm climates. Bull World Health Organ 1974, 51:333-347.
88. Triki H., Ould Mohamed Abdallah M.V., Ben Aissa R., Bouratbine A., Ben Ali Kacemj M., Bouraouil S., et al. Influence of host related factors on the antibody response to trivalent oral polio vaccine in Tunisian infants. Vaccine 1997, 15:1123-1129.
89. Posey D.L., Linkins R.W., Oliveria M.J., Monteiro D., Patriarca P.A. The effect of diarrhea on oral poliovirus vaccine failure in Brazil. J Infect Dis 1997, 175(S1):S258-S263.
90. John T.J., Jayabal P. Oral polio vaccination of children in the tropics: I. The poor seroconversion rates and the absence of viral interference. Am J Epidemiol 1972, 96:263-269.
91. Murdin A.D., Barreto L., Plotkin S. Inactivated poliovirus vaccine: past and present experience. Vaccine 1996, 14:735-746.
92. Melnick J.L. Advantages and disadvantages of killed and live poliomyelitis vaccines. Bull World Health Organ 1978, 56:21-38.
93. Herremans T.M.P.T., Reimerink J.H.J., Buisman A.M., Kimman T.G., Koopmans M.P.G. Induction of mucosal immunity by inactivated poliovirus is dependent on previous mucosal contact with live virus. J Immunol 1999, 162:5011-5018.
94. Faden H. Poliovirus vaccination: a trilogy. J Infect Dis 1993, 168:25-28.
95. Benyesh-Melnick M., Melnick J.L., Rawls W.E., Wimberly J.B., Ben-Porath E., Rennick V. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. Am J Epidemiol 1967, 86:112-136.
96. Marine W.M., Chin T.D., Gravelle C.R. Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. Am J Hyg 1962, 76:173-195.
97. Sutter R., Kew O., Cochi S. Poliovirus vaccine-live. Vaccines 2008, Elsevier Health Sciences, ch 26:631-686. 5th Edition. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
98. World Health Organization Polio vaccines and polio immunization in the pre-eradication era: WHO position paper. Wkly Epidemiol Rec 2010, 85:213-228.
99. Ehrenfeld E., Chumakov K. Monovalent oral poliovirus vaccines-a good tool but not a total solution. N Engl J Med 2008, 359:1726-1727.
100. Aylward R.B., Sutter R.W., Heymann D.L. OPV cessation-the final step to a "polio-free" world. Science 2005, 310:625-626.
101. World Health Organization. Framework for national policy makers in OPV-using countries. WHO/POLIO/05.02. Geneva: WHO; 2005.
102. Modlin J.F. The bumpy road to polio eradication. N Engl J Med 2010, 362:2346-2349.
103. Dowdle W.R., De Gourville E., Kew O.M., Pallansch M.A., Wood D.J. Polio eradication: the OPV paradox. Rev Med Virol 2003, 13:277-291.
104. John T.J. Role of injectable and oral polio vaccines in polio eradication. Expert Rev Vaccines 2009, 8:5-8.
105. Sabin A.B., Ramos-Alvarez M., Alvarez-Amezquita J., Pelon W., Michaels R.H., Spigland I., et al. Live, orally given poliovirus vaccine. JAMA 1960, 173:1521-1526.
106. CDC assessment of risks to the global polio eradication initiative (GPEI) strategic plan 2010-2012.2011(4th quarter report): http://www.polioeradication.org/Dataandmonitoring/Polioeradicationtargets/Riskassessments.aspx.